SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~July~~ 19November 5, 2019 (~~July~~October 1230, 2019)

CALMARE THERAPEUTICS INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware	001-08696	36-2664428
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	1375 Kings Highway East
	Fairfield, CT 06824
	(Address of principal executive offices)
	203-368-6044
	(Registrant’s Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item~~ITEM 58.0201 ~~Departure~~OTHER ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~EVENTS.

~~(d)~~As Onset ~~July~~forth ~~12,~~in ~~2019,~~ the ~~board~~Registrant’s ~~of directors~~Form (10-K for the ~~“Board”)~~fiscal ofyear ~~Calmare~~ended ~~Therapeutics~~December ~~Incorporation~~31, 2016 (the “~~Registrant~~2016 10-K”), ~~elected~~on ~~Dr.~~August ~~Santanu Das~~22, to2014, ~~fill~~GEOMC filed a complaint against the ~~vacancy~~Registrant onin the ~~Board~~United ~~created~~States byDistrict ~~Carl~~Court ~~O’Connell’s~~for ~~resignation~~the District of Connecticut. ~~There~~The ~~was~~allegations noincluded ~~arrangement~~in orthat ~~understanding~~complaint, ~~between~~as Dramended, are described in the 2016 10-K. ~~Das~~On ~~and~~September ~~any~~29, 2017, the District Court entered a final judgment that awarded GEOMC, among other ~~person~~relief, ~~pursuant~~monetary damages of $4,673,406, in addition to ~~which~~pre-judgment Drinterest of $5,678,764, with both amounts totaling $10,352,170. ~~Das~~On ~~was~~May ~~elected~~25, 2018, the District Court entered an order awarding GEOMC attorneys’ fees in the amount of $836,442.05 and costs in the amount of $5,231.80.

OnCalmare ~~July~~appealed ~~12,~~both ~~2019~~the final judgment and the May 25, ~~Dr.~~2018 ~~Das~~order ~~was~~awarding ~~elected~~GEOMC attorneys’ fees and costs to the ~~executive~~ ~~committee~~United States Court of Appeals for the ~~Board.~~Second DrCircuit. As ~~Das~~set isforth ~~party~~in tothe aRegistrant’s ~~non~~Forms 8-~~exclusive~~K ~~consulting~~dated ~~agreement~~March ~~with~~18, ~~the~~2019 ~~Registrant~~and ~~pursuant~~dated toJune ~~which he~~10, ~~provides~~2019, ~~certain~~the ~~advisory~~United ~~services~~States toCourt of Appeals for the ~~Registrant~~Second ~~and~~Circuit heon ~~receives~~March $512,~~000~~ ~~per~~2019 ~~month~~vacated ~~plus~~the ~~expenses~~District Court’s judgment and aremanded ~~commensurate~~the ~~equity~~case to the District Court ~~component~~for infurther ~~compensation~~proceedings.

~~Item~~On ~~8.01~~October ~~Other~~30, ~~Events~~2019, the United States Court of Appeals for the Second Circuit vacated the District Court’s May 25, 2018 order awarding GEOMC attorneys’ fees and costs and remanded the case to the District Court for further proceedings.

OnThe ~~July~~information ~~12,~~in ~~2019,~~this ~~the~~Item ~~Board~~8.01 ~~established~~of anthis ~~executive~~Form ~~committee~~8-K ~~(the~~is being furnished and shall not be deemed “~~Committee~~filed”) offor the ~~Board~~purposes ~~consisting~~ of ~~Peter~~Section ~~Brennan,~~18 ~~Rustin~~of ~~Howard,~~the ~~Conrad~~Securities ~~Mir and~~Exchange ~~Santanu~~Act ~~Das.~~of ~~Pursuant~~1934, or otherwise subject to ~~Section~~the ~~141(c)(1)~~liabilities of ~~the~~that ~~Delaware~~section. ~~General~~The ~~Corporate~~information ~~Law~~in ~~(“DGCL”),~~this ~~the~~Item ~~Board~~8.01 ~~authorized the~~of ~~Committee,~~this inForm ~~its~~8-K ~~discretion,~~also shall not be deemed to ~~exercise~~be ~~any~~incorporated ~~and~~by ~~all~~reference ~~powers~~into ofany ~~the~~filing ~~Board~~under ~~for~~the ~~management~~Securities Act of ~~the~~1933, ~~Company~~as ~~except~~amended, ~~for~~or ~~those~~the ~~powers~~Securities ~~specifically~~Exchange ~~prohibited~~Act ~~from~~of ~~being~~1934, ~~granted~~except to athe ~~committee~~extent ofthat the ~~board~~Company ofspecifically ~~directors~~incorporates ~~under~~it ~~Section~~by ~~141(c)(1) of the DGCL~~reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

July 19, 2019

November 5, 2019

	By:	/s/ Conrad Mir
		Conrad Mir Chief Executive Officer

By: /s/ Conrad Mir Conrad Mir Chief Executive Officer

Filing Compare · CALMARE THERAPEUTICS Inc